AstraZeneca and Daiichi Sankyo announce positive results from phase 3 lung cancer study
AstraZeneca (AZ) and Daiichi Sankyo have announced positive results from a late-stage study of their investigational TROP2-targeting antibody drug conjugate, datopotamab deruxtecan, in certain lung cancer patients. The phase 3 TROPION-Lung01 trial has been …